Since assessing tumor mutational burden requires whole exome NGS profiling, how do you decide which tumor subtypes and patients, are appropriate for comprehensive genomic profiling?

Since assessing tumor mutational burden requires whole exome NGS profiling, how do you decide which tumor subtypes and patients, are appropriate for comprehensive genomic profiling?

Since assessing tumor mutational burden requires whole exome NGS profiling, and given the emerging pervasiveness of immunotherapy for many tumor types, how do you decide which tumor subtypes and patients, especially those with advanced disease, are appropriate for comprehensive genomic profiling?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Samuel Klempner, MD

Samuel Klempner, MD

Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA